Why is there no single price for Ozempic or Zepbound?

Because four different payment routes exist for the same molecule: the list price a pharmacy is billed, the manufacturer's own cash price, your insurance copay, and compounded pricing from telehealth pharmacies. Nobody pays the list price directly, but people with high deductibles or coinsurance can be exposed to it.

Is the cheapest option always the compounded one?

Advertised compounded pricing is currently the lowest published number, but compounded drugs are not FDA-approved products and the agency does not review them for safety, effectiveness, or quality before they are marketed. That is a different product category, not a discount on the same one.

Are these prices going to change?

Yes, and fast. Novo Nordisk announced on 24 February 2026 that the list price of Wegovy, Ozempic, and Rybelsus will drop to $675 a month effective 1 January 2027. Manufacturer self-pay offers carry explicit expiry dates. Treat every figure here as a snapshot.

Does TrackPep sell or supply any of these medications?

No. TrackPep is a logging app. We do not sell medication, recommend a supplier, take referral fees, or help anyone obtain a prescription. We report published prices so you can budget and track what you actually spend.

GLP-1 Cost Guide 2026: Why the Same Drug Has Four Different Prices

The four prices, side by side

Prices checked 2 September 2026; these change often.

There is no such thing as "the price of Zepbound". There are four, and which one applies to you depends on paperwork rather than pharmacology.

Route	What it is	Published figure (2 Sep 2026)
Brand list price	What the manufacturer publishes as the price before rebates. Nobody writes this cheque directly, but deductibles and coinsurance are calculated from it.	Ozempic: $997.58–$1,027.51 per month, depending on presentation
Manufacturer self-pay	The drug company's own cash price, bought direct, no insurance involved	Zepbound KwikPen: $299 (2.5 mg) to $699 (15 mg); Wegovy pill from $149; Wegovy pen from $199 promotional, then $349
Insurance copay	What your plan charges you. Not published by anyone, because it is a property of your plan, not the drug.	Manufacturer cards advertise "as little as $25/month" where the plan covers the drug
Compounded telehealth	A licensed pharmacy prepares the drug against a prescription. Not an FDA-approved product.	RonanRx advertises tirzepatide medication from $78/month plus a $39/month physician fee, renewing "starting at $117/month"

Every one of those numbers is the same two molecules — semaglutide and tirzepatide. The spread between the top and bottom row is roughly tenfold.

Route 1: the list price

Novo Nordisk publishes Ozempic's list price on its own NovoCare site at $997.58–$1,027.51 per month across the 0.25/0.5 mg, 1 mg, and 2 mg pens (the page shows both figures against different presentations). This is the number that matters if you have a high-deductible plan or coinsurance, because your share is computed from it before any rebate reaches you.

It is about to move. On 24 February 2026 Novo Nordisk announced that "effective January 1, 2027, the company will lower the list price… to $675" for Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5, 1 and 2 mg, and Rybelsus tablets 7 and 14 mg — described in the release as reductions "of approximately 50% and 35% for Wegovy and Ozempic, respectively". The same release states plainly that "these changes in list price do not impact other access efforts, including direct-to-patient, self-pay prices."

Not published: we could not find a manufacturer page stating a current list price for Wegovy or Zepbound. Widely reported figures exist; we are not repeating an unsourced number here.

Route 2: manufacturer self-pay

Both manufacturers now sell direct at a cash price far below list.

Zepbound (tirzepatide), from Lilly's own savings page: "Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg." A separate purchase offer brings 7.5 mg through 15 mg to $449 per month provided refills are kept up; Lilly's terms state the offer is automatic on first purchase and lapses if you miss the refill window. The self-pay headline reads "Self-pay, starting at $299 for a 1-month prescription of the Zepbound KwikPen for single-patient use or 4 vials."

Mounjaro (tirzepatide), same molecule, diabetes indication: Lilly's savings page offers "as little as $25" for a 1-, 2-, or 3-month fill where commercial insurance covers the drug, and "as low as $499 for a 1-month prescription fill of Mounjaro single-dose pen" where commercial insurance does not cover it. See Zepbound vs Mounjaro pricing for why one molecule has two prices.

Wegovy and the Wegovy pill, from NovoCare: the oral form is listed as self-pay "starting at $149 per month for the 1.5 mg dose", with the page noting "$149 for each month of 1.5 mg and 4 mg. 4 mg offer only available until August 31, 2026, then $199 per month for 4 mg", and $299 for the 9 mg and 25 mg strengths. The pen is advertised at $199/month for new patients ("offer for 2 monthly fills through December 31, 2026, then $349 per month" for 0.25 through 2.4 mg), with Wegovy HD 7.2 mg at $399/month. Novo also lists a Medicare GLP-1 Bridge price of $50/month for eligible patients; Lilly advertises the same $50 Medicare figure for Zepbound.

Note the shape of these offers: dose strengths are pricing tiers. They are not a dosing recommendation, and nothing on this page is.

Route 3: insurance

We are not going to print an "average copay", because there isn't one. Coverage for obesity indications is inconsistent across commercial plans in a way that coverage for the diabetes indication is not, which is the practical reason the same molecule is cheaper for some people under one brand name than the other.

The only figures either manufacturer publishes are the savings-card floors: "as little as $25" per fill where a commercial plan covers the drug, subject to annual caps (Lilly's Zepbound card is capped at "up to $1,300 per calendar year"; the Mounjaro card at "up to $1,950"), and both cards expire 12/31/2026. Government beneficiaries are excluded from commercial savings cards.

Route 4: compounded telehealth

This is where the price floor collapsed, and it is the row that needs the most care.

RonanRx, on its own product page fetched 2 September 2026, advertises a tirzepatide ladder priced by strength: medication at $78, $88, $108, $128, $148 and $168 per 30 days for the 2.5 through 15 mg tiers under a launch discount (undiscounted: $195 to $345), plus a flat $39/month physician fee, renewing at "starting at $117/month, depending on prescribed dose". Shipping is described as "temperature-controlled, overnight or two-day air", and the page says "cancel anytime".

The same vendor states the crucial caveat itself: "Compounded medicines are prepared by a licensed pharmacy and are not FDA-approved, and they are not reviewed by the FDA for safety or effectiveness."

The FDA puts it identically: "Compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." The agency has also warned that some compounded products use salt forms — "semaglutide sodium and semaglutide acetate" — which "are different active ingredients than are used in the approved drugs", and has reported adverse events "some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products".

So the bottom row of that table is not a cheaper version of the top row. It is a different regulatory category at a lower price. What changed to make it legal, and what enforcement has followed, is covered in compounded vs brand GLP-1: what changed in 2026, and what a patient can actually verify is in is compounded semaglutide safe: what to check.

What this means for budgeting

The headline monthly figure is not your cost. Your cost is what you paid divided by the doses you actually got out of the vial or pen — which is why a $299 tier and a $449 tier can end up closer together than they look, and why a missed or wasted dose is money. If you want to work that out for your own log rather than from a brochure, see how to track GLP-1 cost per dose.

The spokes

Compound reference pages: tirzepatide and semaglutide.

TrackPep is a tracker. It records what you log and never recommends or calculates amounts.